Jennifer Webster
About Jennifer Webster
Jennifer Webster serves as the Vice President and Program Lead at Fulcrum Therapeutics, bringing extensive experience in strategic life cycle and portfolio planning from her previous roles at Foundation Medicine and Vertex Pharmaceuticals.
Current Role at Fulcrum Therapeutics
Jennifer Webster serves as Vice President, Program Lead at Fulcrum Therapeutics since 2021. In this role, she oversees program management and strategic initiatives within the organization. Her focus includes optimizing product development processes and ensuring effective regulatory submissions. Webster's leadership contributes to Fulcrum's mission of advancing innovative therapies for patients with genetic diseases.
Previous Experience at Foundation Medicine
Prior to her current position, Jennifer Webster held the role of Vice President at Foundation Medicine from 2016 to 2021. During her tenure in Boston, Massachusetts, she gained significant experience in strategic life cycle and portfolio planning. Webster successfully managed various functions to enhance innovative product development and regulatory processes, contributing to the company's growth in precision medicine.
Career at Vertex Pharmaceuticals
Jennifer Webster worked at Vertex Pharmaceuticals in multiple roles from 2004 to 2013. She served as Sr Outsourcing Manager and Outsourcing Manager for two years, followed by positions as Associate Director of Medical Alliances & Grants and Sr Clinical Program Manager. Her experience at Vertex encompassed managing clinical programs and fostering collaborations that advanced the company's therapeutic initiatives.
Educational Background
Jennifer Webster holds a Master of Business Administration (MBA) from the University of Massachusetts Boston. She also earned a Bachelor of Arts (B.A.) in Psychology from the University of Rochester. Additionally, she completed her early education at Milton Academy, which laid the foundation for her academic and professional pursuits.
Expertise in Product Development
Jennifer Webster possesses extensive expertise in managing and optimizing product development across various therapeutic areas. She has led the development and launch of six first-in-class products, including oncologic companion diagnostics and treatments for multiple myeloma, cystic fibrosis, and HCV. Her proficiency extends to managing complex budgets exceeding $85 million and unifying stakeholders from biopharma, academia, and patient advocacy groups.